naturalX secures €100m to fuel the future of consumer health in Europe
The new fund supports of NaturalX, which has its first closing at €100m, supports proactive healthcare, filling a market gap as consumers take control of their own health journey.
naturalX Health Ventures has closed a new consumer health-focussed venture capital fund at €100m. The fund is designed to invest mainly across Europe at Series-A stage while also looking at late seed and Series-B series funding rounds. naturalX is backed by Schwabe Group that is engaged in plant-based pharmaceuticals.
As healthcare systems get more and more exhausted in financial terms, there are two major trends in life sciences: firstly, reduce cost and time-to-market by means of automated lead identification and optimisation approaches, clinical trails design and enrolment, digitised process development, scale up and batch release, quality and regulatory compliance management as well as AI-driven personalised marketing approaches, Second, 4P medicine which includes personalisation of diagnosis and treatment, prevention, prediction and patient participation, which puts consumers in the driver’s seat.
While the US market has seen the rise of consumer-centric healthcare champions like Hims/Hers, Headspace, and Function Health, Europe’s market remains underserved, according to naturalX. The venture capitalists’ €100m fund is dedicated to support European consumer health-focussed start-up companies that are active in sleep, mental health, probiotics and gut health, prevention, and longevity such as UK-based clock.bio, Storm Therapeutics, and Genflow Biosciences.
Focussed on Series-A investments, typical first investments will range from €3-5m, with up to €10m available per company. naturalX can act as either lead investor or co-investor, targeting consumer health startups across Europe with selected investments in North America.
naturalX founder Marvin Amberg defines consumer health as the intersection of wellness and medicine, represented by portfolio investments including mybacs, Flow Neuroscience, Kyan Health, and Meela. “The consumer health space has been overlooked by investors,” he said. “We see an inflection point in Europe now, as consumers are finally taking more charge of their own health.”
Following the recent closing, the fund is now fully operational and actively building its cross-European investment team.
